Literature DB >> 27429037

Perioperative Hydrocortisone Reduces Major Complications After Pancreaticoduodenectomy: A Randomized Controlled Trial.

Matias Laaninen1, Juhani Sand, Isto Nordback, Kaija Vasama, Johanna Laukkarinen.   

Abstract

OBJECTIVES: The aim of this study was to study whether post-pancreaticoduodenectomy complications (PPDC) in high-risk patients can be reduced with hydrocortisone.
BACKGROUND: Soft pancreas is a well-known risk factor for PPDC. Previously, we have shown that patients with >40% acini in the pancreatic transection line are most prone to PPDC. Recent studies have demonstrated that surgical trauma leads to inflammation of the pancreatic remnant, which precedes PPDC.
METHODS: On the basis of power analysis, randomized controlled trial (RCT) (Clinicaltrials.gov NCT01460615), 155 patients (February 2011-May 2015) scheduled for pancreaticoduodenectomy were randomized to intravenous (i.v.) treatment with hydrocortisone 100 mg or placebo. All patients received the first dose at the induction of anesthesia. During the operation, the percentage of acini was calculated from pancreatic transection line frozen samples by a pathologist. As planned, only the high-risk patients with >40% acini (n = 62) continued in the study to receive in total 8 doses of randomization-based hydrocortisone/placebo every 8 hours. Primary endpoints were urine trypsinogen positive days and overall complications (Clavien-Dindo III-IV). Postoperative pancreatic fistulas (POPFs), postpancreatectomy hemorrhage (PPH), and delayed gastric emptying (DGE) were also graded.
RESULTS: Hydrocortisone treatment did not alter trypsinogen release (2 or more positive days 46% vs 50%), but it significantly reduced overall complications compared with placebo in the high-risk patients (18% vs 41%; P < 0.05; Clavien-Dindo III-IV). Also, clinically significant POPF (11% vs 27%), PPH (14% vs 24%), and DGE (29% vs 44%) tended to be lower in the hydrocortisone group. Ninety-day mortality was zero.
CONCLUSIONS: This RCT shows that in high-risk patients, overall PPDC can be significantly reduced with hydrocortisone treatment. Inflammation may be an important mediator of PPDC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27429037     DOI: 10.1097/SLA.0000000000001883

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

1.  Flange Gastroenterostomy Results in Reduction in Delayed Gastric Emptying after Standard Pancreaticoduodenectomy: A Prospective Cohort Study.

Authors:  Adeel S Khan; Greg Williams; Cheryl Woolsey; Jingxia Liu; Ryan C Fields; Majella M B Doyle; William G Hawkins; Steven M Strasberg
Journal:  J Am Coll Surg       Date:  2017-07-04       Impact factor: 6.113

2.  Risk Factors and Clinical Impacts of Post-Pancreatectomy Acute Pancreatitis After Pancreaticoduodenectomy: A Single-Center Retrospective Analysis of 298 Patients Based on the ISGPS Definition and Grading System.

Authors:  Shuai Wu; Hanxue Wu; Guiping Xu; Yaling Zhao; Feng Xue; Shunbin Dong; Liang Han; Zheng Wang; Zheng Wu
Journal:  Front Surg       Date:  2022-07-04

3.  Algorithm-based care for early recognition and management of complications after pancreatic resection: toward standardization of postoperative care.

Authors:  Charles de Ponthaud; Sébastien Gaujoux
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

4.  Perioperative Glucocorticoids are Associated with Improved Recurrence-Free Survival After Pancreatic Cancer Surgery: A Retrospective Cohort Study with Propensity Score-Matching.

Authors:  Yun-Xiao Zhang; Dong-Liang Mu; Ke-Min Jin; Xue-Ying Li; Dong-Xin Wang
Journal:  Ther Clin Risk Manag       Date:  2021-01-22       Impact factor: 2.423

5.  The Impact of Preoperative Dexamethasone on the Magnitude of the Postoperative Systemic Inflammatory Response and Complications Following Surgery for Colorectal Cancer.

Authors:  Stephen T McSorley; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan
Journal:  Ann Surg Oncol       Date:  2017-03-01       Impact factor: 5.344

6.  Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula: A Randomized Clinical Trial.

Authors:  Timo Tarvainen; Jukka Sirén; Arto Kokkola; Ville Sallinen
Journal:  JAMA Surg       Date:  2020-04-01       Impact factor: 14.766

7.  Dynamic prediction for clinically relevant pancreatic fistula: a novel prediction model for laparoscopic pancreaticoduodenectomy.

Authors:  Runwen Liu; Yunqiang Cai; He Cai; Yajia Lan; Lingwei Meng; Yongbin Li; Bing Peng
Journal:  BMC Surg       Date:  2021-01-04       Impact factor: 2.102

8.  Perioperative Use of Glucocorticoids and Intraoperative Hypotension May Affect the Incidence of Postoperative Infection in Patients with Gastric Cancer: A Retrospective Cohort Study.

Authors:  Yunxiao Zhang; Shuo Li; Chao Yan; Jiheng Chen; Fei Shan
Journal:  Cancer Manag Res       Date:  2021-10-08       Impact factor: 3.989

9.  Effect of Propofol or Etomidate as General Anaesthesia Induction on Gastric Cancer: A Retrospective Cohort Study with 10 Years' Follow-Up.

Authors:  Xianfu Lu; Yue Yu; Yan Wang; Yi Lyu
Journal:  Cancer Manag Res       Date:  2022-08-08       Impact factor: 3.602

Review 10.  Postoperative pancreatic fistula: a review of traditional and emerging concepts.

Authors:  Christopher B Nahm; Saxon J Connor; Jaswinder S Samra; Anubhav Mittal
Journal:  Clin Exp Gastroenterol       Date:  2018-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.